ATE461698T1 - Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden - Google Patents

Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden

Info

Publication number
ATE461698T1
ATE461698T1 AT98945758T AT98945758T ATE461698T1 AT E461698 T1 ATE461698 T1 AT E461698T1 AT 98945758 T AT98945758 T AT 98945758T AT 98945758 T AT98945758 T AT 98945758T AT E461698 T1 ATE461698 T1 AT E461698T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
gastrointestinal diseases
gaba analogues
gaba
Prior art date
Application number
AT98945758T
Other languages
English (en)
Inventor
Antonio Guglietta
Charles Taylor
Jiayuan Ren
W P Watson
Michael RAFFERTY
Laurent Diop
Maria Chovet
Lionel Bueno
Hilary J Little
Original Assignee
Warner Lambert Co
Regents For The University Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE461698(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co, Regents For The University Of filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE461698T1 publication Critical patent/ATE461698T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT98945758T 1997-08-20 1998-08-18 Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden ATE461698T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5675397P 1997-08-20 1997-08-20
US7479498P 1998-02-16 1998-02-16
US8293698P 1998-04-24 1998-04-24
PCT/US1998/017082 WO1999008671A1 (en) 1997-08-20 1998-08-18 Gaba analogs to prevent and treat gastrointestinal damage

Publications (1)

Publication Number Publication Date
ATE461698T1 true ATE461698T1 (de) 2010-04-15

Family

ID=27369092

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98945758T ATE461698T1 (de) 1997-08-20 1998-08-18 Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden

Country Status (25)

Country Link
US (2) US6242488B1 (de)
EP (1) EP1009399B1 (de)
JP (1) JP4681116B2 (de)
KR (2) KR20050116168A (de)
AT (1) ATE461698T1 (de)
AU (2) AU8668598A (de)
BR (1) BR9812133A (de)
CA (1) CA2297163C (de)
CO (1) CO4960645A1 (de)
CY (1) CY1109981T1 (de)
DE (1) DE69841574D1 (de)
DK (1) DK1009399T3 (de)
ES (1) ES2341154T3 (de)
HU (1) HUP0004551A3 (de)
IL (1) IL134164A (de)
IS (1) IS2749B (de)
MY (1) MY155223A (de)
NO (1) NO327983B1 (de)
NZ (1) NZ502729A (de)
PE (1) PE107299A1 (de)
PL (1) PL194125B1 (de)
PT (1) PT1009399E (de)
TW (2) TW570794B (de)
UY (1) UY25148A1 (de)
WO (2) WO1999008670A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
AU750578B2 (en) 1997-09-08 2002-07-25 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1031350A1 (de) * 1999-02-23 2000-08-30 Warner-Lambert Company Verwendung eines Gabapentin-Analogen zur Herstellung eines Arzneimittels zur Prophylaxe und Behandlung von Eingeweideschmerzen
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
CA2370030C (en) * 1999-04-09 2007-08-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
EP1840117A1 (de) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- und disubstituierte 3-Propyl-gamma-aminobuttersäure
US6310098B1 (en) 1999-07-22 2001-10-30 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
WO2001088101A2 (en) * 2000-05-16 2001-11-22 Warner-Lambert Company CELL LINE FOR THE EXPRESSION OF AN α2δ2 CALCIUM CHANNEL SUBUNIT
EP1343805A4 (de) 2000-10-06 2005-07-20 Xenoport Inc Von gallensäuren abgeleitete verbindungen für die bereitstellung anhaltender systemischer konzentrationen von arzneimitteln nach oraler verabreichung
WO2002032376A2 (en) 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1226820A1 (de) * 2001-01-26 2002-07-31 Warner-Lambert Company Verwendung von bicyclische Aminosäuren zur Prophylaxe und Behandlung von Eingeweideschmerzen und gastrointestinalen Erkrankungen
WO2002100347A2 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100344A2 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
CA2459470C (en) * 2001-09-03 2010-10-12 Patricia Salvati Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
IL162932A0 (en) * 2002-02-22 2005-11-20 Warner Lambert Co Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
AU2003222033A1 (en) 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003247042A1 (en) * 2002-07-10 2004-02-02 Warner-Lambert Company Llc Gastrointestinal compositions comprising gaba derivatives
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP1572187A1 (de) * 2002-12-13 2005-09-14 Warner-Lambert Company LLC Pregabalin und derivate davon zur behandlung von fibromyalgia und fibromyalgia-gebundenen krankheiten
ES2341240T3 (es) * 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
EP1603890A1 (de) 2003-03-07 2005-12-14 Warner-Lambert Company LLC Tetrazol und oxadiazolon-substituierte &bgr;-aminosäurederivate
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
MXPA06003043A (es) 2003-09-17 2006-05-31 Xenoport Inc Tratamiento o prevencion del sindrome piernas inquietas utilizando prodrogas de analogos gaba.
WO2005037784A2 (en) 2003-10-14 2005-04-28 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
DE602005002253T2 (de) * 2004-03-12 2008-05-29 Warner-Lambert Company Llc C1-symmetrische bisphosphinliganden und deren verwendung bei der asymmetrischen synthese von pregabalin
JP2007530657A (ja) * 2004-04-01 2007-11-01 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｐキラル性ホスホランの調製および不斉合成でのその使用
RS51210B (sr) * 2004-06-21 2010-12-31 Warner-Lambert Company Llc. Dobijanje pregaballina i srodnih jedinjenja
JP5319920B2 (ja) * 2004-09-10 2013-10-16 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ナトリウムおよび／またはカルシウムチャンネル選択的調節因子として活性のある医薬の製造のための（ハロベンジルオキシ）ベンジルアミノ−プロパンアミドの使用
EP1811986B1 (de) 2004-11-04 2014-03-26 XenoPort, Inc. Orale darreichungsformen von gabapentin-prodrug mit verzögerter freisetzung
JP5271087B2 (ja) * 2005-12-22 2013-08-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー カルシウム及び／又はナトリウムチャネル調節物質としての２−フェニルエチルアミノ誘導体
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2008073257A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
WO2009055059A1 (en) * 2007-10-26 2009-04-30 The Scripps Research Institute Methods for treating substance dependence
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
JP5563483B2 (ja) 2008-01-25 2014-07-30 ゼノポート，インコーポレイティド アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
BRPI0919811B1 (pt) 2008-10-08 2022-04-19 Xgene Pharmaceutical Inc Conjugados de gaba e métodos de uso dos mesmos
RU2715680C2 (ru) * 2009-06-22 2020-03-03 ВАЙЕТ ЭлЭлСи Таблетки ибупрофена натрия и способы изготовления фармацевтических композиций, включающих ибупрофен натрия
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
AU2014209028C1 (en) 2013-01-28 2019-08-29 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
CN105997970A (zh) * 2015-12-16 2016-10-12 南昌大学 γ-氨基丁酸在制备胃粘膜保护剂中的应用
WO2017177160A1 (en) * 2016-04-07 2017-10-12 Nevakar Llc Formulation for use in a method of treatment of pain
JP7249670B2 (ja) 2017-10-03 2023-03-31 ネヴァカー インジェクテーブルズ インコーポレイテッド アセトアミノフェン－プレガバリン組み合わせ及び疼痛を処置する方法
AU2019271799B2 (en) 2018-05-14 2023-10-12 Xgene Pharmaceutical Inc. Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin
CN116999560A (zh) * 2022-04-30 2023-11-07 武汉思瓴生物科技有限公司 可治疗疼痛的药物组合及其应用
WO2024173750A2 (en) * 2023-02-17 2024-08-22 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634102A (de)
DE1963925C3 (de) 1969-12-20 1975-07-10 Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg Verfahren zur Herstellung von N hoch 3-Carbalkoxyderivaten des 5,5-Diphenylhydantoins
JPS54110334A (en) 1978-02-16 1979-08-29 Fuji Chem Ind Co Ltd Novel compounded anodyne and antiiinflammatory agent
US4158581A (en) 1978-04-14 1979-06-19 Westinghouse Electric Corp. Method of making magnetic component for direct current apparatus
JPS61221121A (ja) 1985-03-27 1986-10-01 Nitto Electric Ind Co Ltd テ−プ製剤
US4694010A (en) 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
JPH02502546A (ja) 1987-12-22 1990-08-16 ファーカニー、ジョン　ダブリュ 抗ひきつけ剤組成物および方法のためのデキストロルファン相乗的協力剤
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
GB9108362D0 (en) 1991-04-18 1991-06-05 Radoslavov Alexander A pharmaceutical composition suitable for alleviation of headaches,migraine and other painful conditions
JP3856816B2 (ja) 1992-05-20 2006-12-13 ノースウェスターン ユニヴァーシティ 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体
US5234929A (en) 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
JPH06100468A (ja) 1992-09-25 1994-04-12 Kibun Food Chemifa Co Ltd 徐放性組成物
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
JPH06227969A (ja) 1993-02-02 1994-08-16 Masayasu Sugihara 薬品の腸溶性改善方法およびそれにより得られた薬品組成物
US5420270A (en) 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5352638A (en) 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
JPH10505087A (ja) 1994-09-02 1998-05-19 バージニア カマンウェルス ユニバーシティ 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
CN1046199C (zh) 1994-12-13 1999-11-10 凌吉安 复方消炎止痛霜剂
EP0942752B1 (de) * 1996-08-23 2005-04-20 Algos Pharmaceutical Corporation Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
ATE361909T1 (de) * 1996-10-23 2007-06-15 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
HUP0004551A2 (hu) 2001-05-28
TW200412938A (en) 2004-08-01
CY1109981T1 (el) 2014-09-10
WO1999008671A1 (en) 1999-02-25
PL194125B1 (pl) 2007-04-30
MY155223A (en) 2015-09-30
BR9812133A (pt) 2000-07-18
NO20000786D0 (no) 2000-02-17
JP2001515033A (ja) 2001-09-18
UY25148A1 (es) 1999-01-26
KR20010023084A (ko) 2001-03-26
ES2341154T3 (es) 2010-06-15
AU8668598A (en) 1999-03-08
DE69841574D1 (de) 2010-05-06
CA2297163A1 (en) 1999-02-25
NO327983B1 (no) 2009-11-02
NO20000786L (no) 2000-02-17
DK1009399T3 (da) 2010-05-31
IS2749B (is) 2011-08-15
KR20050116168A (ko) 2005-12-09
US20010014698A1 (en) 2001-08-16
EP1009399B1 (de) 2010-03-24
KR100609359B1 (ko) 2006-08-04
TWI251485B (en) 2006-03-21
TW570794B (en) 2004-01-11
PE107299A1 (es) 1999-12-19
AU9293098A (en) 1999-03-08
US6242488B1 (en) 2001-06-05
PT1009399E (pt) 2010-05-21
US6426368B2 (en) 2002-07-30
EP1009399A1 (de) 2000-06-21
PL338705A1 (en) 2000-11-20
IL134164A0 (en) 2001-04-30
IL134164A (en) 2005-05-17
CA2297163C (en) 2001-11-20
IS5361A (is) 2000-01-25
CO4960645A1 (es) 2000-09-25
JP4681116B2 (ja) 2011-05-11
WO1999008670A1 (en) 1999-02-25
NZ502729A (en) 2002-10-25
HUP0004551A3 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
DE69722426D1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
NO20014046L (no) Gabapentinderivater for forhindring og behandling av visceral smerte
BR9911887A (pt) Método para o tratamento da insÈnia
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
DE69527749D1 (de) Kugelförmige Aktivkohle zur Behandlung von Bauchentzündungen
NO996468L (no) Anvendelse av gaba-analoger slik som gabapentin i fremstillingen av et medikament for behandling av betennelsessykdommer
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
ATE484292T1 (de) Chorionic gonadotropin zur behandlung des chronischen schmerzsyndroms des beckens
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
EP0974351A3 (de) Arzneimittel zur Vorbeugung und Behandlung von Magendarmschäden
ATE252903T1 (de) Arzneimittel zur behandlung konvulsivischer zustände
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
ATE305778T1 (de) Behandlung von nierenkolik mit gaba-analogen
ATE211914T1 (de) Wismuth enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden
BR9812265A (pt) Uso de análogos de gaba, tais como gabapentina, na fabricação de um medicamento para o tratamento de doenças inflamatórias.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1009399

Country of ref document: EP